Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: HPV16/18; pBI-11; pBI-11 plasmid DNA; pBI-11/TA-HPV; PVX-7

Latest Information Update: 23 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PAPIVAX
  • Class Antineoplastics; Cancer vaccines; DNA vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Human papillomavirus infections

Most Recent Events

  • 18 Jan 2024 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins plans a phase II trial in Human papillomavirus infections (Intradermal, IM) in January 2024 (NCT06210854)
  • 14 Apr 2023 Preclinical trials in Human papillomavirus infections in USA (IM), before April 2023 (PapiVax Biotech pipeline, April 2023)
  • 14 Apr 2023 PapiVax Biotech in collaboration with Vanderbilt University Medical Center (VUMC) plans a phase II trial for Human papillomavirus infections (Metastatic disease, Recurrent, Late-stage disease, First-line therapy) in USA (IM) (NCT05799144)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top